ANI Pharmaceuticals, Inc. $ANIP Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC boosted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 39.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 38,508 shares of the specialty pharmaceutical company’s stock after acquiring an additional 10,975 shares during the quarter. Intech Investment Management LLC’s holdings in ANI Pharmaceuticals were worth $3,040,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Illinois Municipal Retirement Fund increased its stake in ANI Pharmaceuticals by 1.7% during the third quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock worth $782,000 after acquiring an additional 145 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its stake in ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after acquiring an additional 198 shares during the last quarter. Oregon Public Employees Retirement Fund increased its stake in ANI Pharmaceuticals by 5.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock worth $323,000 after acquiring an additional 200 shares during the last quarter. Hantz Financial Services Inc. increased its stake in ANI Pharmaceuticals by 202.6% during the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after acquiring an additional 237 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in ANI Pharmaceuticals by 30.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock worth $86,000 after acquiring an additional 253 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

ANIP has been the subject of several recent analyst reports. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $107.33.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, SVP Thomas Andrew Rowland sold 4,772 shares of the firm’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total transaction of $357,470.52. Following the completion of the transaction, the senior vice president directly owned 38,730 shares in the company, valued at $2,901,264.30. This trade represents a 10.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Nikhil Lalwani sold 55,000 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $77.57, for a total value of $4,266,350.00. Following the transaction, the chief executive officer owned 349,889 shares of the company’s stock, valued at approximately $27,140,889.73. This represents a 13.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 88,950 shares of company stock valued at $6,900,618. Corporate insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Trading Down 2.7%

ANIP opened at $74.65 on Wednesday. ANI Pharmaceuticals, Inc. has a 52 week low of $59.61 and a 52 week high of $99.50. The business has a fifty day simple moving average of $78.77 and a 200-day simple moving average of $79.57. The firm has a market cap of $1.70 billion, a P/E ratio of 18.90 and a beta of 0.44. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. During the same period last year, the business posted $1.70 earnings per share. The company’s quarterly revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts expect that ANI Pharmaceuticals, Inc. will post 7.96 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.